Bronchiolitis in hospitalized babies: a national observation
Part of Infections, Lungs & breathing clinical trials.
This study is watching babies under 1 year old who are in the hospital with bronchiolitis. Doctors want to learn more about the virus and how the new preventive shot (nirsevimab) is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 12 months old.
- Your child must be hospitalized for bronchiolitis (a lung infection that causes coughing and breathing problems).
- Your child must be treated at one of the 12 specific hospitals in the study.
- Your child must have had a test for RSV (the virus that often causes bronchiolitis).
- You need to know if your child got the nirsevimab shot (a preventive medicine) this RSV season.
- Your child must be hospitalized between October 15, 2025 and February 15, 2026.
- You cannot have received the abrysvo RSV vaccine for pregnant women after September 1, 2025.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the germs in a baby's gut and their immune system respond to bronchiolitis (a common lung infection). If your baby is under 12 months and gets bronchiolitis during the RSV season, their participation could help us understand why some babies get very sick and others don't.
This study looks at children hospitalized with bronchiolitis (a lung infection that causes coughing and breathing trouble). It aims to understand what makes some children more likely to get very sick. By joining, researchers can learn more about risk factors and how to help children recover better.
This study looks at how well the new nirsevimab vaccine works against bronchiolitis in babies. If your infant has their first bout of bronchiolitis and gets a nose swab, they may be able to help researchers understand how the virus spreads and how to better protect other babies.
This trial looks at how well the drug nirsevimab works for babies hospitalized with RSV bronchiolitis. It also studies the body's immune response and the baby's environment. The goal is to see if nirsevimab can help infants recover from this serious lung infection.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
Hear when a new Bronchiolitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.